Drug Monograph
Full clinical overview, indications, dosage references & safety notes.
Overview
Chlorambucil (Leukeran®) is an alkylating antineoplastic agent of the nitrogen mustard class used in veterinary medicine as both a chemotherapeutic and immunosuppressive drug in dogs and cats. It is commonly administered orally and is used in the management of certain malignancies as well as some immune-mediated diseases.
Chlorambucil exerts its cytotoxic effect primarily through alkylation of cellular DNA, leading to cross-linking of DNA strands and inhibition of cellular replication. This ultimately results in apoptosis of rapidly dividing cells. In addition to its antineoplastic properties, chlorambucil also produces immunosuppressive effects, which may take 2–4 weeks to become clinically apparent.
After oral administration, chlorambucil is rapidly absorbed and extensively metabolized in the liver to an active metabolite (phenylacetic acid mustard), which contributes to its therapeutic effects. The drug and its metabolites are primarily eliminated through urinary excretion.
Indications
Chlorambucil is used in dogs and cats as an antineoplastic and immunosuppressive agent for the management of certain cancers and immune-mediated diseases. It may be administered alone or as part of combination chemotherapy protocols.
- Lymphoproliferative malignancies: Commonly used in the treatment of conditions such as chronic lymphocytic leukemia and certain forms of lymphoma.
- Metronomic chemotherapy protocols: May be incorporated into low-dose continuous chemotherapy regimens aimed at controlling tumor growth and inhibiting tumor angiogenesis.
- Immune-mediated diseases: Used as an immunosuppressive agent in disorders such as protein-losing enteropathy and other immune-mediated conditions when additional immunosuppression is required.
- Feline dermatologic immune disorders: May be beneficial in the treatment of conditions such as feline pemphigus foliaceus and severe feline eosinophilic granuloma complex.
- Myeloproliferative disorders: Can be used in the management of certain bone marrow–derived proliferative diseases.
Dosage (Reference)
Dog
Chlorambucil is administered orally in dogs and is commonly given with food to reduce gastrointestinal irritation. Dosage varies depending on the disease being treated and the chemotherapy protocol used. Careful monitoring of blood counts is required due to the risk of bone marrow suppression.
| Clinical use | Route | Dose | Frequency | Notes |
|---|---|---|---|---|
| Chronic lymphocytic leukemia | PO | 2–6 mg/m² every 24 hours | q24-48h (per protocol) | Given initially until remission is achieved, then reduced dose or frequency for maintenance. Often combined with prednisolone. |
| Alternative protocol for chronic lymphocytic leukemia | PO | 0.2 mg/kg every 24 hours for 7 days, then 0.1 mg/kg every 24 hours | q24-48h (per protocol) | Maintenance dose used after the initial treatment phase. |
| Pulsed dosing protocol | PO | 20 mg/m² every 1–2 weeks | q24-48h (per protocol) | Used in some chemotherapy protocols. |
| Lymphoma | PO | 15–20 mg/m² every 2 weeks | q24-48h (per protocol) | Typically administered with prednisolone. |
| Lymphoma (alternative protocol) | PO | 2–6 mg/m² every 24–48 hours | q24-48h (per protocol) | May be used depending on chemotherapy protocol. |
| Substitute for cyclophosphamide (CHOP-type protocol) | PO | 1.4 mg/kg single dose | q24-48h (per protocol) | Used as an alternative alkylating agent in chemotherapy protocols. |
| Pemphigus complex (with corticosteroids) | PO | 0.1–0.2 mg/kg every 24 hours | q24-48h (per protocol) | Continue until marked improvement, then transition to alternate-day dosing for several weeks. |
| Protein-losing enteropathy and other immune-mediated diseases | PO | 2–6 mg/m² every 24 hours | q24-48h (per protocol) | Continue until clinical remission, then taper to the minimum effective dose. |
| Metronomic chemotherapy | PO | 4 mg/m² every 24 hours | q24-48h (per protocol) | Low-dose continuous therapy used for tumor control. |
• Give with food to reduce gastrointestinal irritation.
• Dosages are commonly calculated based on body surface area (mg/m²) rather than body weight.
• Regular CBC monitoring is required due to risk of myelosuppression.
• Dose adjustments may be necessary depending on response and hematologic results.
Cat
In cats, chlorambucil is frequently used in the treatment of lymphoid malignancies and immune-mediated diseases. It is administered orally with food and dosing schedules vary depending on the disease and clinical response.
| Clinical use | Route | Dose | Frequency | Notes |
|---|---|---|---|---|
| Immune-mediated disease | PO | 2 mg/cat every 48 hours (cats >4 kg) | q24-48h (per protocol) | Given for 2–4 weeks initially, then tapered to the lowest effective dose. |
| Immune-mediated disease (smaller cats) | PO | 2 mg/cat every 72 hours (cats <4 kg) | q24-48h (per protocol) | Initial dosing for smaller cats. |
| Chronic lymphocytic leukemia | PO | 2 mg/m² every 48 hours | q24-48h (per protocol) | May be used with or without prednisolone. |
| Alternative CLL protocol | PO | 20 mg/m² every 14 days | q24-48h (per protocol) | Pulsed dosing protocol. |
| Low-grade (small cell) lymphoma | PO | 20 mg/m² once every 2 weeks | q24-48h (per protocol) | Typically administered with prednisolone. |
| Substitute for cyclophosphamide (CHOP protocol) | PO | 1.4 mg/kg single dose | q24-48h (per protocol) | Alternative alkylating agent in chemotherapy protocols. |
| Pemphigus foliaceus or severe eosinophilic granuloma complex | PO | 0.1–0.2 mg/kg every 24 hours | q24-48h (per protocol) | Used with corticosteroids until clinical improvement, then reduced to alternate-day dosing. |
• Administer with food to reduce gastrointestinal irritation.
• Hematologic monitoring (CBC) is essential because bone marrow suppression may occur.
• Dose adjustments are commonly required based on clinical response and laboratory results.
Warnings & Precautions
Chlorambucil is a cytotoxic chemotherapy agent that requires careful patient selection, monitoring, and safe handling. Because of its effects on rapidly dividing cells and its immunosuppressive properties, several precautions should be considered when using this drug in dogs and cats.
- Bone marrow suppression: Chlorambucil can cause dose-dependent myelosuppression (anemia, leukopenia, thrombocytopenia). Use cautiously in patients with pre-existing bone marrow depression or those receiving other myelosuppressive drugs.
- Active infections: Immunosuppression may worsen systemic infections. Therapy should be used cautiously in animals with active infectious disease.
- Hepatic impairment: Because chlorambucil is metabolized in the liver, dose adjustments or careful monitoring may be necessary in patients with hepatic dysfunction.
- Hazardous drug handling: Chlorambucil is classified as a hazardous chemotherapy drug. Appropriate precautions such as wearing gloves and minimizing exposure are recommended during handling and administration.
- Pregnancy risk: Chlorambucil is a known teratogen. Avoid use in pregnant animals unless the therapeutic benefit clearly outweighs potential fetal risks.
- Fertility effects: Alkylating agents may impair fertility and reproductive function; caution should be exercised when administering to breeding animals.
- Monitoring requirements: Regular hematologic monitoring (CBC) is necessary during treatment to detect early signs of bone marrow suppression and guide dose adjustments.
Drug Interactions
Chlorambucil may interact with other medications that affect bone marrow function or immune response. Careful monitoring and risk assessment are recommended when combining chlorambucil with the following drugs.
- Myelosuppressive agents (e.g., other antineoplastics, immunosuppressants, iron chelators): Concurrent use may result in additive bone marrow suppression, increasing the risk of anemia, leukopenia, or thrombocytopenia. Combination therapy should be used cautiously and requires close hematologic monitoring.
- Vaccines (live or inactivated): Chlorambucil may reduce vaccine effectiveness due to immunosuppression and may increase the risk of adverse vaccine reactions.
Side Effects & Overdose
Side Effects
Adverse effects associated with chlorambucil therapy in dogs and cats are primarily related to bone marrow suppression and gastrointestinal toxicity. The severity and frequency of adverse effects may increase with higher doses or prolonged treatment.
- Myelosuppression: The most common and clinically significant adverse effect. This may include anemia, leukopenia, and thrombocytopenia. Bone marrow suppression often develops gradually, with nadirs typically occurring about 7–14 days after initiating therapy.
- Severe bone marrow depression: Rarely, prolonged therapy may lead to severe pancytopenia that can take months to years for complete recovery.
- Gastrointestinal toxicity: Vomiting and diarrhea may occur, particularly when higher pulse doses are administered.
- Hepatotoxicity: Elevations in liver enzymes and liver toxicity have been reported in dogs receiving chlorambucil.
- Alopecia and delayed hair regrowth: Some dogs, particularly breeds with continuously growing coats (such as poodles, terriers, Afghan hounds, and Old English sheepdogs), may experience hair loss or delayed regrowth after clipping.
- Neurologic effects: Rare neurologic signs such as twitching, agitation, myoclonus, or seizures have been reported in cats and dogs.
- Fanconi syndrome (cats): Rare cases have been reported in cats receiving chlorambucil with corticosteroids; partial or complete recovery may occur after discontinuation.
Overdose
Information on chlorambucil overdose in veterinary patients is limited. Reported cases in humans indicate that acute overdoses can cause severe bone marrow suppression and neurologic toxicity.
- Neurologic toxicity: High doses may lead to neurologic signs including seizures or severe CNS disturbances.
- Pancytopenia: Marked bone marrow suppression can occur, often developing within 1–6 weeks following overdose.
- Management: Treatment is primarily supportive and may include gastrointestinal decontamination if recent ingestion occurred, close CBC monitoring for several weeks, and blood component therapy when indicated.
- Dialysis: Chlorambucil is not effectively removed by dialysis.
Key Notes
Important clinical considerations that may assist veterinarians when using chlorambucil in dogs and cats in oncology or immunosuppressive treatment protocols:
- Delayed immunosuppressive effect: Clinical immunosuppressive activity may not become apparent for several weeks after starting therapy, so response to treatment may be gradual.
- Active metabolite formation: Chlorambucil is converted in the liver to the active metabolite phenylacetic acid mustard, which contributes significantly to its antineoplastic activity.
- Body surface area dosing: Many oncology protocols calculate chlorambucil dosing using body surface area (mg/m²) rather than body weight, particularly in chemotherapy regimens.
- Combination therapy: Chlorambucil is commonly administered with corticosteroids such as prednisolone in several treatment protocols for lymphoid malignancies and immune-mediated disorders.
- Hair coat considerations: Dogs with continuously growing hair coats may be more prone to noticeable hair coat changes during therapy.
- Chemotherapy safety practices: Because chlorambucil is classified as a hazardous chemotherapy drug, careful storage and handling procedures should always be followed to reduce occupational exposure.
Calculate Any Dose Instantly
Use our smart dose calculator to get accurate dosing for 500+ veterinary drugs — adjusted for species, weight, and route.
